Two common variants in the gene encoding complement factor H (CFH), the Y402H substitution (rs1061170, c.1204C>T) 1-4 and the intronic rs1410996 SNP 5,6 , explain 17% of age-related macular degeneration (AMD) liability. However, proof for the involvement of CFH, as opposed to a neighboring transcript, and knowledge of the potential mechanism of susceptibility alleles are lacking. Assuming that rare functional variants might provide mechanistic insights, we used genotype data and high-throughput sequencing to discover a rare, high-risk CFH haplotype with a c.3628C>T mutation that resulted in an R1210C substitution. This allele has been implicated previously in atypical hemolytic uremic syndrome, and it abrogates C-terminal ligand binding 7,8 . Genotyping R1210C in 2,423 AMD cases and 1,122 controls demonstrated high penetrance (present in 40 cases versus 1 control, P = 7.0 × 10 −6 ) and an association with a 6-year-earlier onset of disease (P = 2.3 × 10 −6 ). This result suggests that loss-of-function alleles at CFH are likely to drive AMD risk. This finding represents one of the first instances in which a common complex disease variant has led to the discovery of a rare penetrant mutation.
Age-related macular degeneration is the leading cause of late-onset blindness in the industrialized world 9 . Common CFH variants are associated with AMD and meningitis susceptibility. Rare CFH mutations cause atypical hemolytic uremic syndrome (aHUS), an episodic illness that causes acute renal failure, and membranoproliferative glomerulonephritis type II (MPGNII), a chronic renal disease 10, 11 . The possibility that rare CFH variants confer AMD risk has been raised 12 , but no rare variant conferring risk of advanced AMD has yet been identified.
To identify rare penetrant variants in the CFH locus, we phased genotypes for 20 common SNPs spanning the CFH-CFHR1-CFHR3 region and a common CFHR1-CFHR3 deletion (CFHR1-3∆) in 711 individuals with advanced AMD (cases) and 1,041 controls ('Boston-phased' data set) 13, 14 . Controls included 304 phenotyped controls without evidence of retinal disease and 737 unphenotyped controls (shared from the MIGen study; see Online Methods) who were presumed not to have disease. Almost all these markers are associated with AMD in our data ( Supplementary Table 1 ). We defined 11 common haplotypes (>0.3% frequency), explaining 97.4% of 3,354 chromosomes, and calculated association statistics ( Fig. 1a and Supplementary Table 2 ). Consistent with previous observations [1] [2] [3] [4] , the most frequent haplotype (H1) is present in 59% of case chromosomes but only 37% of control chromosomes; this haplotype exclusively contains the Y402H 1-4 risk allele (in linkage disequilibrium (LD) with rs10801555, r 2 = 0.99 in 288 genotyped controls). Two haplotypes, H2 and H3, which contain a proxy to the rs1410996 CFH intronic risk SNP 5, 6 , rs10737680, conferred intermediate risk (odd ratio (OR) = 0.59 (0.49-0.71) relative to H1). Excepting H4, the remaining haplotypes contained none of the two common risk variants, and in aggregate they conferred low risk (OR = 0.30 (0.26-0.36) relative to H1).
Notably, 10 of 11 individuals who were heterozygous for the rare H5 haplotype had AMD. This proportion corresponded to an H5 allelic odds ratio that was significantly greater than that of the high-risk H1 haplotype (see Fig. 1 ). The unaffected individual was a 49-year-old unphenotyped male, unlikely to have advanced disease given his age. This proportion of H5 heterozygous individuals with disease was especially unexpected because H5 lacked both the Y402H and rs10737680-rs1410996 risk alleles. We speculated that a rare variant on the H5 haplotype might explain the data. However, before pursuing a sequencing experiment, we considered that the haplotype association might be the consequence of chance or stratification. Therefore, we asked (i) whether the H5 haplotype was associated significantly A rare penetrant mutation in CFH confers high risk of age-related macular degeneration with disease, accounting for known AMD-associated common variants; (ii) whether H5 correlated with earlier age of onset; and (iii) whether the H5 association could be explained by case-control stratification or recent ancestry.
We assessed the statistical significance of the association of H5 with advanced AMD by permuting case-control status across all 1,752 subjects. Because we wanted to conservatively assess whether the association was independent of known risk alleles, we were careful to preserve genotypes for four published AMD-associated common markers: Y402H (rs1080155), rs10737680-rs1410996, CFHR1-3∆ and rs800292 (c.184G>A, resulting in a V62I substitution). This permutation fixes case-control allele frequencies, association statistics and odds ratios at those markers, and also constrains association statistics at the other 17 markers as a result of underlying LD in the region (Supplementary Fig. 1 ). Although common marker association statistics are maintained in these permutations, we rarely observed ten or more affected heterozygous H5 individuals (P = 0.00081; Fig. 1b ). Permuting case-control status without preserving marker genotypes or preserving genotypes at only two common markers (Y402H and rs1410996) yielded similar results (P = 0.00081 and P < 0.00001, respectively). Thus, the case association with this haplotype is beyond what might be expected by chance.
The ten H5 heterozygous individuals were diagnosed earlier than were the other 701 cases in the Boston-phased data set (median age 62.5 years versus 71 years, P = 0.0023, one-tailed rank-sum test), further suggesting that H5 might influence AMD risk.
To assess the possibility that the H5 association might be the consequence of recent relatedness or population stratification, we selected 79,091 independent SNPs from genome-wide data (see Online Methods). We noted first that there was only modest genome-wide stratification (λ GC = 1.08) 13 . We projected genotype data into principal components 14 and observed that H5 heterozygotes did not cluster discretely (Supplementary Fig. 2 ) and that H5 heterozygous individuals were not skewed along any of the top 20 components (P > 0.047; Supplementary Table 3 ). To confirm that H5 was not the consequence of a recent common ancestry, we estimated the proportion of identity by descent to be <3% between H5 heterozygous pairs; at least ~12.5% would be expected for first cousins or more closely related relatives. Taken together, our data suggest that the observed H5 association is unlikely to be artifactual.
To discover the causal mutation, we designed a sequencing experiment. We selected 84 samples representing all 11 haplotypes, including homozygous individuals when possible, and included all ten affected individuals with H5. We first applied high-throughput sequencing to a 106.7-kb region containing the CFH introns, exons and promoter. We sequenced a subset of 60 individuals (33 cases and 27 controls) representing each of the 11 haplotypes. These samples included six individuals heterozygous for H5. We achieved high coverage, with 80% of individuals sequenced at ≥20× for at least 89.3 kb ( Supplementary Fig. 3 ). Genotype calls from sequencing were 98.9% accurate in 19 separately genotyped SNPs. We identified a total of 623 variants; to avoid false positive calls, we focused our analyses on 356 variants seen at least twice (Supplementary Tables 4 and 5). We were confident that H5-specific CFH alleles, both coding and noncoding, were likely to be among these as two or more H5 heterozygotes achieved >20× coverage in 97.8% of the targeted region. Figure 1 A rare CFH haplotype is associated with AMD risk. (a) Phasing 21 markers in the CFH-CFHR3-CFHR1 region. Here we present association statistics of 11 haplotypes with frequencies >0.3%, resulting from phasing 20 SNP markers and a CFHR1-CFHR3 common copy-number polymorphism. We specifically note the CFH rs800292 SNP (encoding the V62I substitution); the CFH Y402H substitution proxy, rs10801555; CFH rs1410996 proxy, rs10737680; and CFHR1-3∆. For most SNPs we list the nucleotide; for CFHR1-3∆, the empty circles indicate the region that is deleted, whereas the filled circles indicate the region that is not deleted. To the right of each haplotype, we note the observed frequency in cases and controls. To the far right of each haplotype, we plot the ratio of the odds of disease for each haplotype relative to H1. Beside the H5 odds ratio, for comparison we note the aggregate odds ratio of haplotypes H4-H11 depicted with a red dot. (b) Case-control permutations preserving genotype at four common AMD-associated markers. Here we present a histogram of the number of H5 heterozygous individuals who are cases for each of the 100,000 permutations. An arrow is placed at 10, corresponding to the observed number of H5 heterozygous individuals who are cases in the actual data (P = 0.00081). Figure 2 Sequencing the H5 haplotype identifies an R1210C-encoding mutation. We applied capillary electrophoresis sequencing to 84 individuals representing the common CFH haplotypes depicted in Figure 1 . Each circle represents an individual. The position on the grid indicates the two haplotypes for the individual at the CFH locus; individuals along the diagonal are homozygous for a haplotype. Individuals who do not have the R1210C mutation are depicted with an empty circle and those heterozygous for the R1210C mutation with a filled red circle. All ten individuals with the R1210C mutation are heterozygous for the H5 haplotype, strongly suggesting that the mutation is on that haplotype and accounts for the increased risk associated with that haplotype. 1 2 3 4 VOLUME 43 | NUMBER 12 | DECEMBER 2011 Nature GeNetics l e t t e r s
We found only six nonsynonymous alleles: (i) rs800292 (yielding the V62I substitution); (ii) rs1061170 (yielding the Y402H substitution); (iii) rs1065489 (c.2808G>T, yielding an E936D substitution); (iv) rs35274867 (c.3148A>T, yielding an N1050Y substitution);
(v) a rare c.2850G>T variant (yielding a Q950H substitution); and (vi) a rare c.3628C>T variant in exon 22 (yielding an R1210C substitution) ( Supplementary Fig. 4a ). Of all the observed variants, only the R1210C variant was seen exclusively in all of the six sequenced H5 heterozygous individuals. To confirm that R1210C was specific for H5, we used capillary electrophoresis to sequence exon 22 in all 84 samples ( Supplementary Fig. 4b ).
Only the ten affected individuals with the H5 haplotype had the R1210C mutation ( Fig. 2) ; we concluded that R1210C was specific for H5. We found no other exon 22 variants in any of these 84 individuals.
To confirm the R1210C association and to assess its presence on other haplotypic backgrounds, we genotyped 707 out of the 711 cases, and 303 out of 304 examined controls, from the Boston-phased data set ( Table 1) . We observed 13 individuals who were heterozygous for R1210C: in addition to the ten H5 heterozygous individuals, we also identified three more affected individuals with R1210C, two of whom were H1 homozygotes and one of whom was an H1/H11 heterozygote. We did not find the R1210C mutation in any controls. This suggested that, in addition to being present consistently on the H5 haplotype, R1210C was also rarely present on the H1 haplotype. One possibility is that the R1210C mutation initially occurred on the common H1 background, and that the H5 haplotype exists because of a historical recombination with H6. These data suggested that R1210C explained the H5 haplotype association with disease and was associated with advanced AMD (P = 0.0094, one-tailed Fisher's exact test; Table 1 ).
To replicate the R1210C association, we genotyped an independent set of 1,707 cases and 817 controls from the Boston and Baltimore sample sets ( Table 1) . We assessed significance with exact statistics because the R1210C heterozygotes were so rare (see Online Methods). In this independent case-control replication, we observed a statistically significant association (20 in cases versus 1 in controls, one-tailed, P = 0.0052). Combining our case-control replication with the Boston-phased discovery data set, we observed R1210C heterozygotes in 33 out of 2,414 cases (1.4%) compared to 1 out of 1,120 controls (<0.1%), suggesting that this mutation confers a high degree of risk (one-tailed combined, P = 8.0 × 10 −5 ) and acts as an almost fully penetrant allele. As Y402H is an influential risk factor at the population level 1-4 , we also assessed significance by stratifying for the Y402H genotype (see Online Methods). We observed that stratifying on Y402H only increased the significance of the R1210C association (one-tailed, P = 9.1 × 10 −7 ). We concluded that R1210C confers risk independently of the common Y402H risk allele.
To further replicate the R1210C association in independent firstdegree relatives, we identified 11 siblings of 6 cases with R1210C from the Boston-phased and Boston replication data sets. These siblings either were unambiguously affected with advanced AMD (n = 9) or showed no clinical evidence of disease (n = 2) ( Table 1 and Supplementary Table 6 ). We observed that seven of the nine affected individuals, but neither of the two controls, were heterozygous for the R1210C-encoding mutation (one-tailed binomial, P = 0.033). In total, aggregating all of the results from our family and case-control data, we observed a highly significant association (P = 7.0 × 10 −6 , P = 1.3 × 10 −7 stratifying for Y402H; Table 1 ). We estimate that this mutation accounts for an ~14% increase in disease prevalence among siblings of affected probands.
As the R1210C-encoding mutation apparently has a strong genetic effect, we tested whether it also drives an early age of disease onset. We observed that unrelated individuals with the R1210C mutation Figure 3 The phenotype of the R1210Cencoding mutation. (a) Histogram of the age of onset for 23 individuals with the R1210C mutation, and also for 1,887 individuals without the R1210C mutation from the Boston-phased data and Boston replication for whom data was available. Age of onset is defined as the age when the patient starts to show signs of AMD. The median age of diagnosis for affected individuals with the R1210C mutation is 6 years younger than those without (65 versus 71 years), and the mean age is 8.6 years younger (61.9 versus 70. Genotyping results of individuals from three case-control collections and also from siblings of individuals in the Boston collections with the R1210C-encoding mutation. The first row shows the results of individuals from the Boston-phased data set, which were used to generate the haplotypes in Figure 1 . The next two rows describe data from two replication collections. The third row presents aggregate statistics of the replication collections. The fourth row presents aggregate statistics from all of the case-control data sets, including both the replication data and the Boston-phased data set. The fifth row presents the results of genotyping siblings of affected individuals with the R1210C mutation. The last row presents statistical significance data of all of the above data sets. For each data set, we present counts of affected and unaffected individuals with and without the R1210C mutation. We also list one-tailed P values for each row, with and without stratifying on the Y402H genotype.
l e t t e r s had significantly earlier disease onset (median of 65 versus 71 years, P = 2.3 × 10 −6 , rank-sum test; Fig. 3a ). Of the 55 individuals with an age of onset <55 years, 5 had the R1210C mutation (8.3%); no individual with onset after 75 years had the R1210C mutation. The retinal phenotype for individual advanced AMD patients with R1210C typically included numerous small, medium and large drusen (Fig. 3b) .
Notably, in our sequencing experiment we found only one rare intronic allele that might potentially contribute to the phenotype; this was a SNP (at 194905360 (HG18)) in five of the six H5 heterozygotes ( Supplementary Table 4 ). However, we consider this allele unlikely to be causal. First, this variant has no evidence of mammalian conservation or regulatory function. Second, applying capillary electrophoresis sequencing to 17 R1210C heterozygous individuals revealed that six lacked the intronic allele, indicating again that the R1210C allele is on multiple haplotypes and that the intronic change is more recent.
The R1210C mutation had been described as an incompletely penetrant allele that causes familial forms of aHUS [15] [16] [17] [18] [19] , and has also been associated with primary glomerulonephritis 20 . This allele has been observed worldwide in multiple families affected with aHUS and in 1-4% of individuals in aHUS cohorts 16 . The R1210C mutation has been shown to compromise C-terminal CFH function; mutant CFH protein has normal cofactor activity but exhibits defective binding to C3d, C3b, heparin and endothelial cells 7, 8, 21 . Moreover, mutant protein product in plasma produces a high-molecular-weight factor H protein, resulting from a covalent interaction with human serum albumin 15 .
Because R1210C is known to cause familial renal disease, we assessed renal function in our patients. We estimated the glomerular filtration rate from serum creatinine measurements in 17 unrelated R1210C heterozygotes with advanced AMD. None had evidence of clinically significant renal dysfunction (creatinine >1.7 mg dl −1 , eGFR <30 ml min −1 ), though we noted subclinical renal dysfunction (median eGFR of 62 ml min −1 ). As AMD patients in general have subclinical renal dysfunction 22 , we compared renal function in these R1210C heterozygotes to that of 17 individuals matched on disease severity, age and gender but without R1210C. We observed no significant difference (one-tailed, P = 0.54; Supplementary Fig. 5) .
A previous study proposed that rare CFH variants might be compound heterozygous alleles acting in trans with common alleles such as Y402H or V62I 12 . We found no evidence of this for the R1210C mutation. For the 13 Boston-phased cases with R1210C (with complete phase information), we observed no excess beyond chance of Y402H risk allele in trans (61% (8 of 13) versus 59% frequency in all cases) or V62I risk allele (85% (11 of 13) versus 87% frequency) in trans.
Our data suggest that compromised CFH function contributes to AMD pathogenesis and facilitates the transition from association to causality that is ubiquitously necessary to advance studies of complex disorders. We do not exclude possible contributions of neighboring CFH-like loci. Nonetheless, abrogated C-terminal activity of this protein represents potentially the first mechanistic clue about pathogenesis and could inform attempts to understand the action of other cis and trans susceptibility alleles. This highlights the value of finding rare alleles with an experimentally tractable biological effect in complex traits.
Our data link two clinically unrelated diseases, AMD and aHUS, with common underlying pathology. We note that AMD is associated with common variants in multiple complement-pathway genes (CFI 23 , CFH 1-6 , CFB 24 and C3 (refs. 4,25) ), and that rare predisposing mutations to aHUS have been observed in these same genes 26 . Future studies sequencing these genes in large numbers of patients might also reveal rare, highly penetrant alleles that could contribute to our understanding of the mechanism of AMD.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
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Study sample descriptions. Case definitions. All individuals, except MIGen shared controls, were evaluated by a board-certified ophthalmologist. For all individuals we either (i) clinically evaluated with visual acuity measurements, dilated slit-lamp biomicroscopy and stereoscopic colour fundus photography or (ii) reviewed ophthalmologic medical records. Case patients had either geographic atrophy (advanced dry AMD) or neovascular disease (wet AMD) (Clinical Age-Related Maculopathy Grading System (CARMS) stages 4 and 5) 27 . Controls were without macular degeneration, and without early or intermediate disease, categorized as stage 1. All Boston controls and most Baltimore samples (>80%) were ≥60 years old. Individuals with early or intermediate disease were excluded from this study.
Boston. Subjects were recruited through ongoing AMD study protocols 5, [28] [29] [30] [31] ; sample ascertainment and genotyping have been described 5, 23, 25 . All samples were unrelated, self-described white individuals of European descent. A subset of these samples was previously genotyped using the Affymetrix SNP 6.0 GeneChip 32 . We combined those samples that passed strict quality control genome-wide with 100% successful SNP and copy number variation (CNV) genotype calls at the CFH locus (n = 711 cases, 304 controls) with shared control samples from the MIGen 33 study passing the same strict quality control criteria (n = 737) to constitute the Boston-phased data set 34 . Remaining unrelated individuals (n = 1,205 cases, 657 controls) constituted the Boston replication sample.
Baltimore. Unrelated subjects recruited at Johns Hopkins Hospital in Baltimore, Maryland, USA, as previously described 32, [35] [36] [37] , who were selfdescribed white individuals of European descent constituted the Baltimore replication collection.
Siblings. For individuals with advanced AMD who had the mutation of interest encoding the R1210C substitution, we identified siblings in the Boston cohort. We included only extremely discordant siblings with advanced AMD or no evidence of disease to avoid ambiguous diagnoses. Sibling samples are independent of the original Boston-phased and Boston replication collections.
High-throughput sequencing. We used long-range PCR to sequence the whole 107-kb region around CFH. We designed long-range PCR primers to be 28-35 nucleotides long to assure high melting temperature and specificity, without G stretches (4+ Gs), without secondary structure and without multiple annealing locations genome-wide ( Supplementary Table 7a ). We used the high-fidelity Takara LA DNA polymerase for PCR amplification. Primers for each amplicon were tested on control DNA for quality control. We selected primer pairs that successfully generated PCR products and, in aggregate, covered the whole region of interest. We used the PreCR (New England Biolabs) repair approach to remediate samples that performed poorly during the PCR amplification step.
We cleaned amplicons using Ampure Beads, quantified using Picogreen and then pooled in equimolar amounts. We constructed libraries with Nextera (Epicentre Biotechnologies). During the subsequent enrichment step, unique index sequences were added to each DNA sample. Ten index libraries were pooled together in a single lane for sequencing. We sequenced pooled index libraries on an Illumina IIGX genome analyzer to generate 50-nucleotide paired-end reads.
We used Burrows-Wheeler Aligner (BWA) 38 to align the short reads to the human genome build GRCh37. Duplicate reads were marked and removed using Picard (http://picard.sourceforge.net/) to avoid recurrent errors in DNA molecules. We performed quality score recalibration and local realignment around indels using the Genome Analysis Tool Kit (GATK) 39 . We called SNP genotypes with the Unified Genotyper module in GATK based on three metrics: mapping quality score, coverage and strand bias (see http://www. broadinstitute.org/software/syzygy/). Low-coverage samples (<10× depth for >20 kb) and samples with >15% genotype error with 19 SNPs genotyped on the Affymetrix array were removed. For this study we required that the minimum mapping quality score be at least 10, coverage be at least 20 and the strand bias be at most 0 (where a positive strand bias suggests that variant reads are emerging predominantly from only one of the two strands).
Confirmation with electrophoresis capillary sequencing. We confirmed genotype for sequenced samples with capillary electrophoresis sequencing using the Applied Biosystems 3730xl platform (see Supplementary Table 7b for primers). We analyzed traces using Phred, Phrap and Consed 40, 41 and identified mutations with Polyphred 42 .
Genotyping R1210C. Once we identified the R1210C mutation, we genotyped it in all available samples-this includes all samples described above with the exception of MIGen shared controls. We genotyped Boston samples at the Clinical and Translation Research Center Core Lab of Tufts Clinical and Translation Science Institute with a custom TaqMan approach ( Supplementary  Table 8 ). We genotyped Baltimore samples at the Duke University Center for Human Disease Modeling using a custom-made TaqMan genotyping assay for CFH R1210C by Applied Biosystems and with the ABI 7900 Real-Time PCR system.
Statistical analyses. Defining haplotypes.
To ensure accurate phasing, the individuals in this data set had 0% missing genotype for CFH markers. For all markers, we constructed haplotypes using the Boston-phased data set across the CFH locus with Beagle 43 and PLINK 44 . We selected haplotypes with frequencies >0.3%, and calculated case and control frequencies. For each haplotype we calculated odds ratios and 95% confidence intervals relative to the most frequent haplotype.
Assessing haplotypic association accounting for common SNP associations. To quantify the probability that the number of H5 heterozygous individuals might be affected by chance, we permuted the case-control status across all 1,752 individuals in the Boston-phased data set. But, to control for the effects of common associated risk alleles, we preserved genotypes at four markers: Y402H (rs1080155), rs10737680-rs1410996, CFHR1-3∆ and rs800292 (V62I), for each individual. We selected those markers because they have been most commonly suggested as causal alleles in the published literature. All individuals were grouped by genotype at each of those four markers, and then case-control status in each group was permuted. We conducted 100,000 permutations. For each permutation we calculated the association statistics and odds ratios for each common marker; using all of the permutations we calculated the 95% confidence range for odds ratios and association statistics for each common marker. To assess the significance of our H5 association we compared the observed number of H5 individuals with disease to the distribution from permuted results. For comparison, we conducted similar analyses in which we permuted case-control status preserving genotype at no markers at all, and preserving genotype at only two markers: Y402H (rs1080155) and rs10737680-rs1410996.
Assessing common ancestry and stratification with genome-wide SNPs. To assess relatedness between samples and population stratification, we used the genome-wide SNP data passing stringent quality control from the Affymetrix array on the Boston-phase samples for all 1,752 samples. We required that SNPs met the following criteria: (i) Hardy-Weinberg with P > 0.001; (ii) missing genotypes <2%; (iii) minor allele frequency >5%. We removed SNPs in regions with known association to AMD, the CFH locus (chr. 1, [194] [195] [196] Mb in HG18 coordinates) and the ARMS2 locus (chr. 10, 123-125 MB), along with SNPs in the highly stratified the major histocompatibility complex (chr. 6, 25-35 Mb) and the chromosome 8 inversion region (chr 8, 7-13 Mb). Pruning SNPs in LD (r 2 < 0.2) to ensure independence resulted in 79,091 SNPs. To assess whether any of the pairs of H5 individuals had a recent common ancestor, we used these SNPs with Plink 44 to estimate identity by descent between pairwise H5 heterozygotes. To assess whether the haplotype association was the consequence of stratification, we applied Eigenstrat to generate principal components for these individuals 14 . Then we separately plotted cases, controls and H5 heterozygotes along the top two principal components. To assess whether H5 individuals were skewed along any of the individual top 20 components, we sampled 11 individuals randomly (to match the number of H5 heterozygotes) 10,000 times. For each component we noted the median value for the H5 heterozygotes and compared it to the medians of the randomly sampled individuals. The P value was the percentage of sampling instances with more-extreme-than-observed median values in either direction.
Selecting samples for sequencing. We aimed to select 90 samples on the basis of available DNA stores for sequencing. We selected only those samples that could be phased into the common identified haplotypes in the CFH locus.
Where possible, we selected six homozygotes for each haplotype randomly from available samples with an equal number of cases and controls. When sufficient numbers of homozygotes were not available, up to 16 heterozygotes were selected randomly with an equal number of cases and controls. We selected samples to ensure that each common haplotype was represented.
Statistical test for association of R1210C. For single-stratum case-control sample collections we used a 2 × 2 Fisher's exact test to calculate a one-tailed P value. Assuming a single stratum in which there are a total of N individuals, of whom n case are cases and n R1210C are heterozygous for the R1210C mutation, we can calculate the one-tailed significance of observing n R1210C,cases individuals who have the R1210C mutation and also have advanced AMD as follows: ) n x n ≤ ≤ ∑ where "hypergeometric" is the hypergeometric probability distribution assuming that there are n R1210C draws from a total of N samples, of which x of a total of n case are drawn. We used this approach to calculate the significance values reported in Table 1 for Boston-phased, Boston replication and Baltimore replication data not stratified on Y402H genotype.
If multiple strata are present-for example, if we are stratifying genotype counts on Y402H genotypes or combining multiple case-control collections together-we expand the above strategy to calculate an exact P value. Assume that we observe a total of n R1210C,case R1210C heterozygotes who are affected across all strata, then, for each stratum j, we can calculate significance as follows: 
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Here, for each stratum j we have separate numbers of total individuals (N j ), separate numbers of individuals who are cases (n j,case ) and individuals with the R1210C genotype (n j,R1210C ). So, we calculate the hypergeometric probability for each individual stratum for all the possible counts that would result in an equal or greater than n R1210C,case total number of heterozygotes associated with advanced AMD, and total these probabilities together to obtain a P-value.
For first-degree siblings, we calculated statistical significance using the binomial distribution. Given that siblings were selected from affected probands who carried the R1210C-encoding mutation, the probability that each additional relative would have the mutation is 0.5. We assign each sibling a score, s i , which is 1 if the sibling has both advanced AMD and R1210C or if the sibling has neither advanced AMD or R1210C, and 0 if the sibling has advanced AMD without R1210C or R1210C without advanced AMD. We obtain an aggregate score by summing over all independent siblings: where the function binomial represents the binomial distribution for x successful draws out of n siblings , each with a 0.5 probability.
To calculate an aggregate meta-analysis, we define a score, s aggregate , that is the total of n R1210C,case across all strata and s. We can calculate the probability of obtaining the score s or a more significant score to determine the exact one-tailed P value: ( , , , )
x i x j y j j j j x N n n … + ∑ Statistical analysis of age of onset. For 1,910 out of 1,912 unrelated individuals affected with advanced AMD from the Boston-phased and Boston replication samples, we had information on age of disease onset. Age of onset is defined as the age at which the individual was first diagnosed with AMD, which might predate the age at which patients fulfilled the case definition of advanced AMD. We used a nonparametric Wilcoxon rank-sum test to test whether affected individuals with the R1210C mutation had earlier age of onset than did those without this mutation.
